Accelerating Medicines Partnership® Program—Common Metabolic Diseases
Identifying novel therapeutic targets across common metabolic diseases
Traditionally, common metabolic diseases have been targeted and treated as individual diseases. Their potential shared molecular basis represents an opportunity to treat multiple diseases simultaneously and to provide more effective treatment outcomes.
The Accelerating Medicines Partnership® Program Common Metabolic Diseases (AMP® CMD) is a precompetitive partnership among government and private-sector partners that harnesses their collective capabilities, scale and resources to therapeutically address multiple metabolic diseases that share common pathogenic drivers and overlapping molecular pathways.
Building on the successful outputs of the AMP T2D program, including rich genetic and genomic datasets on over 1.5 million participants with T2D and related complications, robust analytic tools and innovative predictive algorithms, AMP CMD will generate and acquire data to accelerate target discoveries within and across common metabolic diseases. Through its publicly available knowledge portal, the AMP CMD Knowledge Portal, this initiative will aggregate, analyze and display human genetic and functional genomic data from participants with cardiovascular diseases, kidney diseases and liver diseases such as NASH, obesity, type 2 diabetes and type 1 diabetes. AMP CMD will apply large scale genetic, genomic, transcriptomic and proteomic approaches to characterize human physiology and pathophysiology at cellular, tissue, organ and whole organism levels.
The AMP CMD initiative will prioritize targets for each of the metabolic diseases and develop tools to analyze links between them. As with other AMP programs and the commitment to open access data, information will be made broadly available to the scientific research community with security and ethical protections in place for participants’ data.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and four private partners together fund the 5-year, $57M AMP CMD initiative which will be managed by the FNIH.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Eli Lilly and Company*
- Novo Nordisk*
- Pfizer Inc.*
*Provides financial or in-kind support for this program
- Lynette Nguyen, Ph.D., PMP, Scientific Project Manager, email@example.com
- Tania Kamphaus, M.Sc., Ph.D., Director, Metabolic Disorders, firstname.lastname@example.org
- Expand and evolve the AMP CMD Knowledge Portal and develop new analytic and visualization tools to enable robust therapeutic target discovery and prioritization for new therapeutic approaches to address unmet clinical needs for individuals with common metabolic diseases.
- Generate new data and integrate existing human disease-related data to address prioritized gaps for for therapeutic target discovery for common metabolic diseases, including nonalcoholic steatohepatitis, chronic kidney diseases, obesity, atherosclerotic cardiovascular diseases and heart failure, type 2 diabetes/prediabetes, autoimmune diabetes and inflammatory drivers.
Results & Accomplishments
FNIH Press Release (May 26, 2021): The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases Read more
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.